USPTO serial 79345925
SCT BIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 12, 2023
- Examiner
- LUEKEN, ABIGAIL JOSEPHINE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SCT BIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
CZ
CZ
CZ
CZ
CZ
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shane Rumbaugh
Shane Rumbaugh Rumbaugh Law PLLC2400 Ansys Drive, Suite 102Canonsburg, PA 15317United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 039 | Packaging services in the nature of applications of labels to cell therapy materials; storage and distribution of cell therapy materials | ACTIVE | — |
| 040 | Manufacture of cell therapy materials, namely, autologous and allogenic cell-based therapy pharmaceuticals to the order and specification of others; manufacture of viral and non-viral vectors to the order and specification of others; manufacture of cellular vaccines, car-t therapy materials, namely, chimeric antigen receptor T cell-based pharmaceuticals, tcr-t therapy materials, namely, T cell receptor T cell-based pharmaceuticals, or car-nk therapy materials, namely, chimeric antigen receptor natural killer cell-based pharmaceuticals to the order and specification of others | ACTIVE | — |
| 042 | Pharmaceutical research and development, namely, for cell therapy materials, cellular vaccines, car-t therapies, tcr-t therapies, and car-nk therapies; scientific research and development, namely, for cell therapy materials, cellular vaccines, car-t therapies, tcr-t therapies, and car-nk therapies; consultation in the field of pharmaceutical research and development, namely, for cell therapy materials, cellular vaccines, car-t therapies, tcr-t therapies, and car-nk therapies; product research and development, namely, for cell therapy materials, cellular vaccines, car-t therapies, tcr-t therapies, and car-nk therapies; biological materials testing services and biological laboratory services, namely, for cell therapy materials, cellular vaccines, car-t therapies, tcr-t therapies, and car-nk therapies; contract research services in the field of cell therapy materials, cellular vaccines, car-t therapies, tcr-t therapies, and car-nk therapies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SCT Cell Manufacturing s.r.o.
- Other trademarks owned by SCT Cell Manufacturing s.r.o.
- Other trademarks owned by SCT Cell Manufacturing s.r.o.
- Other trademarks owned by SCT Cell Manufacturing s.r.o.
- Other trademarks owned by SCTbio a.s.
- Other trademarks in Class 039
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named SCT BIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 5, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 5, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 5, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 2, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 13, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 13, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 12, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 16, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 16, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 16, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 12, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 12, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 26, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 26, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 25, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 6, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 6, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 6, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 24, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 23, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 23, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 23, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 23, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 20, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 20, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 20, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 25, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 25, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 20, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 25, 2022 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Nov 24, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 23, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 22, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 18, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 2, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 29, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 28, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |